Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in acute ischemic stroke
NCT04309474Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of elezanumab in ischemic stroke, sponsored by AbbVie Inc.. Started Nov 2020; status: completed.
02
Drugs
elezanumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04309474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309474.